Skip to main content
SpringerLink
Log in

Biology of PSMA As a Diagnostic and Therapeutic Target

  • Chapter
Management of Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

Abstract

Prostate cancer remains the most common cancer type in men in the United States. Efforts are increasing to evaluate and discover diagnostic and therapeutic markers for prostate cancer patients. One of these, prostate-specific membrane antigen (PSMA), is a transmembrane protein highly expressed in all types of prostatic tissue, especially cancer. The radioimmunoconjugate form of the anti-PSMA monoclonal antibody (MAb) 7E11, known as the ProstaScint® scan, is currently being used to diagnose prostate cancer metastasis and recurrence. The antibody used in the ProstaScint scan recognizes an intracellular epitope of PSMA, making it most accessible in cells that are dead. The ProstaScint antibody is also a mouse antibody that can result in the generation of human anti-mouse antibodies (HAMAs). Therefore second-generation antibodies have been developed that are either genetically engineered humanized antibodies or are fully human antibodies that recognize the extracellular portion of the PSMA protein. Early promising results from various phase I and II trials have demonstrated the utility of PSMA as a target for both imaging and therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927–936.

    PubMed  CAS  Google Scholar 

  2. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11–C5. Cancer Res 1990; 50: 6423–6429.

    PubMed  CAS  Google Scholar 

  3. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807–1811.

    PubMed  CAS  Google Scholar 

  4. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81–85.

    PubMed  CAS  Google Scholar 

  5. Wright GL, Haley C, Beckett ML, Schelhammer PF. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol 1995; 1: 18–28.

    Article  PubMed  Google Scholar 

  6. Leek J, Lench N, Maraj B, et al. Prostate-specific membrane antigen: evidence for the existence of a second related human gene. Br J Cancer 1995; 72: 583–588.

    Article  PubMed  CAS  Google Scholar 

  7. O’Keefe DS, Su SL, Bacich DJ, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1998; 1443: 113–127.

    Article  PubMed  Google Scholar 

  8. Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific antigen. Cancer Res 1993; 53: 227–230.

    PubMed  CAS  Google Scholar 

  9. O’Keefe DS, Bacich DJ, Heston WDW. Prostate-specific membrane antigen. In: Chung LWK, Isaacs WB, Simmons JW, eds. Prostate Cancer Biology Genetics and the New Therapeutics. Humana, Totowa, NJ, 2001, pp. 307–326.

    Google Scholar 

  10. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996; 2: 1445–1451.

    PubMed  CAS  Google Scholar 

  11. Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 1997; 49 (3A suppl): 104–112.

    Article  PubMed  CAS  Google Scholar 

  12. Heston WDW, Tong WP, Pinto JT. Prostate-specific membrane antigen, a unique folate hydrolase: potential target for producing therapy. Mol Urol 1997; 1: 215–219.

    CAS  Google Scholar 

  13. Neale JH, Bzdega T, Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000; 75: 443–452.

    Article  PubMed  CAS  Google Scholar 

  14. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996; 93: 749–753.

    Article  PubMed  CAS  Google Scholar 

  15. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharm Exp Ther 1998; 286: 1020–1025.

    CAS  Google Scholar 

  16. Rajasekaran SA, Gapalakrishnapillai A, Oshima E, Bowie JU, Liu H, Heston WD. A novel cytoplasmic tail mxxxl motif mediates the internalization of prostate specific membrane antigen. Mol Biol Chem 2003; 14: 4835–4845.

    CAS  Google Scholar 

  17. Anilkumar G, Rajasekaran SA, Wang S, et al. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res 2003; 63: 2645–2648.

    PubMed  CAS  Google Scholar 

  18. O’Keefe DS, Bacich DJ, Heston WDW. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane-like gene. Prostate, in press.

    Google Scholar 

  19. O’Keefe DS, Uchida A, Bacich DJ, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000; 45: 149–157.

    Article  PubMed  Google Scholar 

  20. Watt F, Martorana A, Brookes DE, et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 2001; 73: 243–254.

    Article  PubMed  CAS  Google Scholar 

  21. Uchida A, O’Keefe DS, Bacich DJ, Molloy PL, Heston WD. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology 2001; 58 (2 suppl 1): 132–139.

    Article  PubMed  CAS  Google Scholar 

  22. Lee SJ, Lee K, Yang X, et al. NFATcl with AP-3 site binding specificity mediates gene expression of prostate-specific membrane antigen. J Mol Biol 2003; 18: 330: 749–760.

    Article  Google Scholar 

  23. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 200 1; 1: 61: 3760–3769.

    Google Scholar 

  24. Bacich DJ, Pinto JT, Tong WP, Heston WD. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001; 12: 117–123.

    Article  PubMed  CAS  Google Scholar 

  25. Bacich DJ, Ramadan E, O’Keefe DS, et al. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J Neurochem 2002; 83: 20–29.

    Article  PubMed  CAS  Google Scholar 

  26. Bacich DJ, Wozniak K, May Lu XC, et al. Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and isochemic brain injury, submitted.

    Google Scholar 

  27. Su SL, Huang IP, Fair WR, Powell CT, Heston WD. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995; 55: 1441–1443.

    PubMed  CAS  Google Scholar 

  28. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62: 552–558.

    Article  PubMed  CAS  Google Scholar 

  29. Troyer JK, Beckett ML, Wright GL Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997; 30: 232–242.

    Article  PubMed  CAS  Google Scholar 

  30. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Research 1997; 57: 3629–3634.

    PubMed  CAS  Google Scholar 

  31. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostatespecific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1995; 59: 3192–3198.

    Google Scholar 

  32. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000; 60: 5237–5243.

    PubMed  CAS  Google Scholar 

  33. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM’ protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998; 58: 4787–4789.

    PubMed  CAS  Google Scholar 

  34. Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol 1998; 160: 2396–2401.

    Article  PubMed  CAS  Google Scholar 

  35. Danshe M, Gardner J, Donovan G, et al. Fully human anti-PSMA antibodies for prostate cancer therapy. Proc Am Assoc Cancer Res 2003; 44: 1483 (abstract #6471).

    Google Scholar 

  36. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol, 2003; 170: S84–S88.

    Article  PubMed  Google Scholar 

  37. Murphy GP, Kenny GM, Ragde H, et al. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology 1998; 51 (5A suppl): 89–97.

    Article  PubMed  CAS  Google Scholar 

  38. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58: 4055–4060.

    PubMed  CAS  Google Scholar 

  39. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma a study of 184 cases. Cancer 1998; 82: 2256–2261.

    Article  PubMed  CAS  Google Scholar 

  40. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997; 57: 2321–2324.

    PubMed  CAS  Google Scholar 

  41. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326–334.

    Article  PubMed  Google Scholar 

  42. Chang SS, Reuter VE, Heston WDW, Hutchinson B, Grauer LS, Gaudin PB. Short term neoadjuvant androgen deprivation therapy does not affect prostate-specific membrane antigen expression in prostate tissues. Cancer 2000; 88: 407–415.

    Article  PubMed  CAS  Google Scholar 

  43. Beckett ML, Cazares LH, Vlahou A, Schellhammer PF, Wright GL Jr. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin Cancer Res 1999; 5: 4034–4040.

    PubMed  CAS  Google Scholar 

  44. Moreno JG, Croce CM, Fischer R, et al. Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 1992; 52: 6110–6112.

    PubMed  CAS  Google Scholar 

  45. Israeli RS, Miller WH Jr, Su SL, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994; 54: 6306–6310.

    PubMed  CAS  Google Scholar 

  46. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998; 83: 2259–2269.

    Article  PubMed  CAS  Google Scholar 

  47. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients correlation with pathological stage. Cancer Res 1998; 58: 1456–1459.

    PubMed  CAS  Google Scholar 

  48. Thomas J, Gupta M, Grasso Y, et al. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J Clin Oncol 2002; 1: 20: 3213–3218.

    Article  Google Scholar 

  49. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy analysis of 136 scans of 100 patients. Prostate 1998; 37: 261–269.

    Article  PubMed  CAS  Google Scholar 

  50. Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 1998; 23: 672–677.

    Article  PubMed  CAS  Google Scholar 

  51. Kahn D, Williams RD, Manyak MJ, et al. 1 11Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998;159:2041–2046, discussion 2046–2047.

    Google Scholar 

  52. Kahn D, Williams RD, Seldin DW, et al. Radioimmunoscintigraphy with 1 1 1indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994; 152: 1490–1495.

    PubMed  CAS  Google Scholar 

  53. Polascik TJ, Manyak MJ, Haseman MK, et al. Comparison of clinical staging algorithms and 111InCapromab pendetide immunoscintigraphy to predict lymph node involvement in high-risk prostate cancer patients. Cancer 1999; 85: 1586–1592.

    Article  PubMed  CAS  Google Scholar 

  54. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003; 21: 1715–1721.

    Article  PubMed  CAS  Google Scholar 

  55. Sodee DB, Ellis RJ, Samuels MA, et al. Prostate cancer and prostate bed SPECT imaging with ProstaScint semiquantitative correlation with prostatic biopsy results. Prostate 1998; 37: 140–148.

    Article  PubMed  CAS  Google Scholar 

  56. Elllis RJ, Kim EY, Conant R, et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 2001; 49: 1281–1286.

    Article  Google Scholar 

  57. Michaels EK, Blend M, Quintana JC. Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. J Urol 1999; 161: 597–598.

    Article  PubMed  CAS  Google Scholar 

  58. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen (PSMA). Semin Oncol, 2003; 30: 667–676.

    Article  PubMed  CAS  Google Scholar 

  59. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999; 1: 123–127.

    Article  PubMed  CAS  Google Scholar 

  60. Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36: 39–44.

    Article  PubMed  CAS  Google Scholar 

  61. Murphy GP, Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38: 73–78.

    Article  PubMed  CAS  Google Scholar 

  62. Murphy GP, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM, Jarisch J. Higher dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 2000; 43: 59–62.

    Article  PubMed  CAS  Google Scholar 

  63. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998; 4: 295–302.

    PubMed  CAS  Google Scholar 

  64. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry protein antigens. Clin Cancer Res 1998; 4: 2669–2676.

    PubMed  CAS  Google Scholar 

  65. Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G. The epithelial cell surface antigen 17–1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution, and recognition by different monoclonal antibodies. Intl J Cancer 1986; 38 (1): 47–53.

    Article  CAS  Google Scholar 

  66. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga TM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Onc 1998; 16: 2659–2671.

    CAS  Google Scholar 

Download references

Authors
  1. Sam S. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil H. Bander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Warren D. W. Heston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Urology Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

    Eric A. Klein MD (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Chang, S.S., Bander, N.H., Heston, W.D.W. (2004). Biology of PSMA As a Diagnostic and Therapeutic Target. In: Klein, E.A. (eds) Management of Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-776-5_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-776-5_34

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5711-8

  • Online ISBN: 978-1-59259-776-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation